Video

Immunotherapy revolutionizes frontline treatment in advanced RCC

Author(s):

Urology Times staff

Michael E. Hurwitz, MD, PhD, an associate professor of Internal Medicine at the Yale Cancer Center, discusses how immune checkpoint inhibitor–based combination have dramatically altered the frontline treatment paradigm for patients with advanced renal cell carcinoma.

Related Videos
Ellen Cahill, MD, answers a question during a video interview
Male doctor examining patient | Image Credit: © Rawpixel.com - stock.adobe.com
Blur image of hospital corridor | Image Credit: © zephyr_p - stock.adobe.com
Ellen Cahill, MD, answers a question during a video interview
Chad Tang, MD: Considerations for SBRT in metastatic RCC
Related Content
Identifying unique therapeutic targets for chromophobe kidney cancer
March 6th 2025

Identifying unique therapeutic targets for chromophobe kidney cancer

David A. Braun, MD, PhD Hannah Clarke
“What we hope overall is that this is a biological study that might inform therapeutic development for this disease,” says David A. Braun, MD, PhD.
female doctor talking with male patient
December 22nd 2022

Dr. Katherine Rotker on destigmatizing sexual health

Urology Times staff
"I think there's a lot of fear that can go into talking about these topics," says Katherine Rotker, MD.
Camillo Porta, MD, offers key takeaways from CheckMate 9ER trial in renal cell carcinoma
February 26th 2025

Camillo Porta, MD, offers key takeaways from CheckMate 9ER trial in renal cell carcinoma

Camillo Porta, MD
"At ASCO GU, we presented the final analysis of the study, which confirmed the superiority of a combination over the TKI monotherapy in terms of both progression-free survival as well as overall survival," says Camillo Porta, MD.
Human kidney cross section on science background. 3d render. | Image Credit: © Rasi - stock.adobe.com
February 20th 2025

Final CheckMate 9ER data show long-term efficacy of nivolumab/cabozantinib in RCC

Benjamin P. Saylor
Robert J. Motzer, MD, reported that median PFS was 16.4 months in the nivolumab plus cabozantinib arm (95% CI, 12.5-19.3) vs 8.3 months in the sunitinib arm (95% CI, 7.0-9.7) (HR=0.58, 95% CI, 0.49-0.70).
Belzutifan approved in EU for renal cell carcinoma
February 18th 2025

Belzutifan approved in EU for renal cell carcinoma

Hannah Clarke
The conditional approval of belzutifan is valid for 1 year, with the opportunity for yearly renewal pending forthcoming data.
Human kidney cross section on science background. 3d render. | Image Credit: © Rasi - stock.adobe.com
February 17th 2025

Casdatifan is linked with promising safety, efficacy in clear cell RCC

Benjamin P. Saylor
“Over 80% of patients…had at least 2 lines of therapy, so this is a heavily refractory population,” said Toni K. Choueiri, MD, FASCO.
© 2025 MJH Life Sciences

All rights reserved.